NASDAQ$JAGX
Jaguar Health Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported consolidated financial results and business updates for 2019
Jaguar Health reported strong Mytesi sales growth in 2019 and is planning to initiate three clinical trials in the second half of 2020, subject to additional financing.
- Mytesi net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018.
- The company aims to forge a regional, ex-US business development deal to bring in non-dilutive dollars.
- Plans to complete the roll-out of new patient support program for Mytesi.
- Napo Pharmaceuticals will receive additional preclinical services from the National Institute of Allergy and Infectious Diseases (“NIAID”) to support development of lechlemer.
Headline financials
Revenue & EPS history
Jaguar Health · Revenue · Quarterly
$1.51M
Revenue by segment
Jaguar Health · $20.3M total across 2 segments · Q1 2026
- Human Health$19.9M—98.3%
- Animal Health$345K—1.7%
Forward guidance
Jaguar Health anticipates a transformative year in 2020 with key goals including business development deals, patient support program roll-out, and clinical trial initiations.
Tailwinds
- 2020 has the potential to be a transformative year for the Company
- Forging an ex-US business development deal to bring in non-dilutive dollars to support efforts to move key potential Mytesi pipeline indications into development, commercialization, and access outside the U.S.
- Completing the roll-out of new patient support program for Mytesi
- Planning to initiate three clinical trials in the second half of 2020
- Napo will receive additional preclinical services from NIAID to support development of lechlemer
Headwinds
- Additional financing is needed to initiate three clinical trials in the second half of 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2019
-6.2%
Avg return
Earnings day
-10.0%
Avg return
5 days after
-12.3%
Avg return
30 days after
24%
11 / 45 earnings
Positive
+23.1%
Q3 2023
Best reaction
-36.4%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | -9.6% | — | |
| Q1 2026 | -5.0% | -13.6% | -37.9% | |
| Q3 2025 | +2.9% | -32.0% | -33.1% | |
| Q2 2025 | -17.9% | -25.9% | -24.3% | |
| Q1 2025 | +4.8% | -22.5% | -36.5% | |
| Q4 2024 | +8.8% | -12.6% | +144.8% | |
| Q3 2024 | -4.6% | -10.2% | -11.1% | |
| Q2 2024 | -10.8% | +5.8% | -7.5% | |
| Q1 2024 | -12.2% | -10.7% | -78.7% | |
| Q4 2023 | -17.8% | -6.7% | +150.0% | |
| Q3 2023 | +23.1% | +31.3% | -46.1% | |
| Q2 2023 | -10.8% | -12.6% | -44.9% | |
| Q1 2023 | -31.7% | -32.2% | -28.6% | |
| Q4 2022 | -31.0% | -44.4% | -51.3% | |
| Q3 2022 | -6.7% | -13.3% | -25.3% | |
| Q2 2022 | -8.8% | -8.6% | -32.6% | |
| Q1 2022 | -7.1% | -1.4% | -15.5% | |
| Q4 2021 | -7.4% | +12.8% | +42.5% | |
| Q3 2021 | -16.7% | -20.7% | -35.1% | |
| Q2 2021 | -12.8% | -15.0% | -34.8% | |
| Q1 2021 | -2.4% | +4.7% | +37.8% | |
| Q4 2020 | +13.8% | +14.4% | -13.2% | |
| Q3 2020 | -5.9% | +2.0% | +108.4% | |
| Q2 2020 | -21.3% | -15.3% | -36.5% | |
| Q1 2020 | -1.4% | -0.4% | -1.4% | |
| Q4 2019 | -5.9% | -6.5% | +2.0% | |
| Q3 2019 | -36.4% | -37.9% | -45.0% | |
| Q2 2019 | -23.9% | -27.7% | -16.4% | |
| Q1 2019 | +0.6% | +4.1% | -60.4% | |
| Q4 2018 | -9.8% | -23.9% | -38.6% | |
| Q3 2018 | -4.3% | -8.5% | -33.2% | |
| Q2 2018 | -12.4% | -19.9% | -50.3% | |
| Q1 2018 | -4.4% | -5.7% | -26.6% | |
| Q4 2017 | +4.6% | -1.1% | -9.3% | |
| Q3 2017 | -2.4% | -5.0% | -32.2% | |
| Q2 2017 | -6.3% | -15.4% | -19.7% | |
| Q1 2017 | -1.2% | -0.4% | -16.4% | |
| Q4 2016 | -1.1% | +10.3% | +16.1% | |
| Q3 2016 | -1.9% | -18.8% | -15.8% | |
| Q2 2016 | +3.4% | -6.1% | -23.1% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +5.6% | — | — | |
| Q3 2015 | +8.0% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro